Fig. 4

TOIDC reduces lipid accumulation through regulation of the SREBP1-dependent lipogenesis pathway. A Abundance of mRNAs in primary hepatocytes stimulated by oleic acid (OA) and palmitic acid (PA) previously treated with vehicle or TOIDC. B Representative Nile Red-stained images of the vehicle, TOIDC-treated, and T0901317-treated primary hepatocytes. Scale bar, 100 µm. C Abundance of lipogenesis-related mRNAs in primary hepatocytes stimulated by OA/PA previously treated with vehicle or TOIDC and T0901317. D Abundance of lipogenesis-related mRNAs in HepG2 stimulated by OA/PA previously treated with vehicle or TOIDC. E Abundance of lipogenesis-related mRNAs in HepG2 by OA/PA previously treated with vehicle or TOIDC and T0901317. F Immunoblots (proteins indicated) in vehicle-and TOIDC-treated primary hepatocytes stimulated by OA/PA previously. G Quantification of (F). H Immunoblots (proteins indicated) in vehicle-, TOIDC-and T0901317-treated primary hepatocytes stimulated by OA/PA previously. I Quantification of (H). J Immunoblots (proteins indicated) in vehicle-and TOIDC-treated HepG2 stimulated by OA/PA previously. K Quantification of (J). L Immunoblots (proteins indicated) in the vehicle, TOIDC, and T0901317 treated HepG2 stimulated by OA/PA previously. M Quantification of (L). Data are presented as mean ± SEM of three independent biological replicates; *P < 0.05; **P < 0.01; ns no significance